Is Turnstone Biologics Stock a Good Investment?
Turnstone Biologics Investment Advice | TSBX |
- Examine Turnstone Biologics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Turnstone Biologics' leadership team and their track record. Good management can help Turnstone Biologics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Turnstone Biologics' business and its evolving consumer preferences.
- Compare Turnstone Biologics' performance and market position to its competitors. Analyze how Turnstone Biologics is positioned in terms of product offerings, innovation, and market share.
- Check if Turnstone Biologics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Turnstone Biologics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Turnstone Biologics Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Turnstone Biologics Corp is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Possible Manipulator | Details |
Examine Turnstone Biologics Stock
Researching Turnstone Biologics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 66.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 0.22. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Turnstone Biologics Corp recorded a loss per share of 3.23. The entity had not issued any dividends in recent years.
To determine if Turnstone Biologics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Turnstone Biologics' research are outlined below:
| Turnstone Biologics generated a negative expected return over the last 90 days | |
| Turnstone Biologics has some characteristics of a very speculative penny stock | |
| Turnstone Biologics has high historical volatility and very poor performance | |
| Turnstone Biologics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 19.31 M. Net Loss for the year was (55.2 M) with profit before overhead, payroll, taxes, and interest of 71.13 M. | |
| Turnstone Biologics generates negative cash flow from operations | |
| Turnstone Biologics has a frail financial position based on the latest SEC disclosures | |
| About 66.0% of the company shares are owned by institutional investors |
Turnstone Biologics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Turnstone Biologics Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Turnstone Biologics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 8th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Turnstone Biologics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.39 M.Basic technical analysis of Turnstone Stock
As of the 27th of March, Turnstone Biologics has the Risk Adjusted Performance of (0.02), variance of 25.09, and Coefficient Of Variation of (2,864). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Turnstone Biologics Corp, as well as the relationship between them.Turnstone Biologics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Turnstone Biologics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Turnstone Biologics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Turnstone Biologics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Turnstone Biologics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Turnstone Biologics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.58) | |||
| Mean Deviation | 3.99 | |||
| Coefficient Of Variation | (2,864) | |||
| Standard Deviation | 5.01 | |||
| Variance | 25.09 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.17) | |||
| Treynor Ratio | (0.59) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.33 | |||
| Skewness | 0.0947 | |||
| Kurtosis | (0.58) |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.58) | |||
| Mean Deviation | 3.99 | |||
| Coefficient Of Variation | (2,864) | |||
| Standard Deviation | 5.01 | |||
| Variance | 25.09 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.18) | |||
| Total Risk Alpha | (0.17) | |||
| Treynor Ratio | (0.59) | |||
| Maximum Drawdown | 20.01 | |||
| Value At Risk | (7.69) | |||
| Potential Upside | 8.33 | |||
| Skewness | 0.0947 | |||
| Kurtosis | (0.58) |
Consider Turnstone Biologics' intraday indicators
Turnstone Biologics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Turnstone Biologics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 2679.15 | |||
| Daily Balance Of Power | (0.33) | |||
| Rate Of Daily Change | 0.98 | |||
| Day Median Price | 0.4 | |||
| Day Typical Price | 0.4 | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 40.42 |
Turnstone Stock media impact
Far too much social signal, news, headlines, and media speculation about Turnstone Biologics that are available to investors today. That information is available publicly through Turnstone media outlets and privately through word of mouth or via Turnstone internal channels. However, regardless of the origin, that massive amount of Turnstone data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Turnstone Biologics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Turnstone Biologics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Turnstone Biologics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Turnstone Biologics alpha.
Turnstone Biologics Corporate Management
| Ines MD | Senior Development | Profile | |
| Michael Fitch | Senior Manufacturing | Profile | |
| Vijay MBA | Interim Officer | Profile | |
| Campisi Esq | Chief Officer | Profile | |
| David Stojdl | Senior Discovery | Profile |
Additional Tools for Turnstone Stock Analysis
When running Turnstone Biologics' price analysis, check to measure Turnstone Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Turnstone Biologics is operating at the current time. Most of Turnstone Biologics' value examination focuses on studying past and present price action to predict the probability of Turnstone Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Turnstone Biologics' price. Additionally, you may evaluate how the addition of Turnstone Biologics to your portfolios can decrease your overall portfolio volatility.